Chagas Disease Treatment Market - Global Industry Insights, Trends, and Opportunity Analysis, 2017-2025
American trypanosomiasis, also referred to as Chagas disease, is caused by the parasite Trypanosoma cruzi (T.cruzi), which is transmitted by the bite of triatomine bugs.
American trypanosomiasis, also referred to as Chagas disease, is caused by the parasite Trypanosoma cruzi (T.cruzi), which is transmitted by the bite of triatomine bugs.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
REPORT DESCRIPTION<br />
<strong>Chagas</strong> <strong>Disease</strong> <strong>Treatment</strong> <strong>Market</strong>: Key Players<br />
●<br />
●<br />
●<br />
●<br />
●<br />
F. Hoffmann-La Roche Ltd.<br />
KaloBios Pharmaceuticals, Inc.<br />
Johnson & Johnson.<br />
Bayer AG.<br />
ELEA SACIF Laboratory.<br />
Adoption of nitro derivative compound drugs associated with the host immune response, help prevent the disease<br />
<strong>and</strong> avoid parasite proliferation. Drugs used in the treatment of <strong>Chagas</strong> disease include benznidazole <strong>and</strong><br />
nifurtimox, however, these are associated with serious side effects such as headaches, skin rashes, photosensitivity,<br />
chest pain, dizziness, nausea, insomnia, <strong>and</strong> jaundice. This poses as a restraining factor for growth of the market.<br />
Browse The Complete Report @<br />
https://www.coherentmarketinsights.com/ongoing-insight/chagas-disease-treatment-market-934<br />
© Coherent market <strong>Insights</strong>. All Rights Reserved
Change language